Physician profile
Natalie Huxtable
NPI 1962167585
$7,223.35
in general payments reported to CMS, 2019-2025
24 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.85 · 2022: $992 · 2023: $2,091 · 2024: $2,159 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,061 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,061.39 |
| Education | $149.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,262.89 | 2022-2025 | |
| Janssen Biotech, INC. | $957.47 | 2022-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $701.80 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.78 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $572.53 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Aimmune Therapeutics, INC. | $286.44 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $260.00 | 2022-2023 | Ibsrela |
| Lilly USA, LLC | $224.90 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $187.40 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $181.61 | 2024-2025 | Voquezna |
| Celgene Corporation | $164.43 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $149.26 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $136.67 | 2022-2024 | Talicia, Movantik, Aemcolo |
| Ironwood Pharmaceuticals, INC | $126.15 | 2023-2024 | Linzess |
| Celltrion USA INC. | $69.85 | 2025 | Vegzelma |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.04 | 2024-2025 | |
| Madrigal Pharmaceuticals | $52.28 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $48.59 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $37.86 | 2022 | |
| Novo Nordisk INC | $19.30 | 2025 | Wegovy |
| Sandoz INC. | $18.67 | 2024 | Hyrimoz |
| Exact Sciences Corporation | $17.08 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $16.83 | 2023 | |
| Intra-Sana Laboratories | $13.52 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Huxtable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.